Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.87 | N/A | -1297.11% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-3.87 | N/A | -1297.11% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the ongoing market conditions affecting performance. They did not provide a clear outlook for future quarters.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in the current market environment.
The earnings report indicates significant challenges for 10X Genomics, particularly reflected in the large EPS miss. The stock's 2.54% decline suggests investor concern over the company's current trajectory and lack of guidance for future performance. Without clear direction from management, investors may remain cautious in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
GRUPO AEROMEXICO S A ADR
Feb 16, 2021